INCA33890 (Not yet branded)

Other Medications

US Experimental Not specified 2 Clinical Trials
KRAS-related pathways

Description

INCA33890 is a targeted therapy compound being developed for the treatment of colorectal cancer, particularly in patients with microsatellite stable (MSS) tumors and KRAS mutations. Based on clinical trial data, it is being tested in combination with standard-of-care chemotherapy and bevacizumab as a first-line treatment for metastatic colorectal cancer. The drug appears to be designed to address treatment-resistant colorectal cancers that harbor specific molecular characteristics.

Mechanism of Action

INCA33890 targets specific molecular pathways associated with KRAS-mutated colorectal cancers, though the exact mechanism of action has not been fully disclosed in available clinical data. The drug is designed to work synergistically with conventional chemotherapy and anti-angiogenic agents to overcome resistance mechanisms commonly seen in MSS colorectal tumors.

Molecular Targets

Side Effects

Specific side effect profile not yet established Likely includes fatigue Gastrointestinal toxicity Hematologic toxicity Skin reactions Hepatic dysfunction Cardiovascular effects Immune-related adverse events

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07284849 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark,
NCT06179160 Phase 1
Recruiting
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
United States, Australia, Belgium, Canada, France, Italy, Japan, Spain

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
AdministrationNot specified
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.